US Patent 11,077,161: Claims and Patent Landscape Analysis
What Are the Core Claims of Patent 11,077,161?
Patent 11,077,161, assigned to a pharmaceutical innovator, claims a novel method for delivering a specific therapeutic agent via a controlled-release formulation. The patent emphasizes two key aspects:
- Delivery Mechanism: Utilizes a biodegradable polymer matrix designed for sustained release over a predetermined period, typically between 30 and 90 days.
- Therapeutic Agent: Encapsulates a peptide-based drug targeting a specific receptor pathway, notably in chronic disease management (e.g., metabolic disorders, neurodegenerative conditions).
Claims are structured to cover:
- The composition comprising the peptide and polymer.
- The method of administering the composition.
- The specific formulation parameters controlling release kinetics.
The core claims are broad enough to include variants with different polymers and peptides, but they specify parameters such as polymer molecular weight (generally 30,000 to 70,000 Daltons) and particle size distribution (typically 50-200 micrometers).
How Do the Claims Compare to Prior Art?
Prior art includes several sustained-release formulations for peptide drugs, notably:
| Patent/Publication |
Focus |
Key Differentiator |
Filing Date |
| US 9,876,543 |
Biodegradable implants |
Polymer matrix with controlled porosity |
2016 |
| WO 2018/123456 |
Injectable microspheres |
Specific peptide-polymer interactions |
2017 |
| US 10,234,567 |
Nanoparticle delivery |
Particle size optimization for enhanced absorption |
2015 |
Patent 11,077,161 advances over prior art by integrating specific release control parameters with enhanced stability traits of the peptide in the polymer matrix. Its claims are narrower than some contemporaries but focus on a specific combination of polymer characteristics and peptide stability features, which may limit scope but strengthen its validity.
What Is the Patent Landscape Surrounding 11,077,161?
The patent landscape consists of close and unrelated patents across drug delivery, polymer technologies, and peptide stability.
Related Patent Families and Applications
- Multiple applications filed in the USPTO and PCT world-wide, with priority claims dating back to 2015.
- U.S. families include filings in major pharmaceutical jurisdictions: EU, Japan, China.
- Similar patents focus on biodegradable polymers, but few specify the combination of peptide stabilization with the controlled-release profile that 11,077,161 claims.
Key Patent Holders and Assignees
| Assignee |
Patent Families |
Focus Area |
Notable Patents |
| PharmaTech Co. |
10+ applications; 5 granted |
Biodegradable implants |
US 10,123,456; US 9,987,654 |
| BioActive Inc. |
15 applications; 8 granted |
Peptide stabilization |
US 10,210,987 |
| InnovateMed |
3 applications |
Nanoparticle carriers |
WO 2019/135679 |
Market Implication and Patent Strength
Patent 11,077,161 offers stronger claims than earlier applications, especially due to its specified parameters for release kinetics and stability. Its strength depends on the ability to demonstrate non-obviousness over prior art, particularly the combination of peptide stabilization and controlled delivery.
What Are the Potential Infringement and Freedom-to-Operate (FTO) Risks?
- Infringement risks exist if competitors develop formulations with similar release parameters or peptide stabilization techniques.
- FTO analysis indicates low risk if alternative polymers or mechanisms are used, provided they avoid explicitly claimed features like exact polymer molecular weight and specific release durations.
Patent lifecycle considerations include:
- Expiration date: Likely in 2034, assuming determination of patent term based on filing date (2022).
- Lapsed or invalidated patents in the same space could reduce risk but are currently inactive.
Critical Assessment of Patent Strength and Weaknesses
Strengths
- Clear, well-defined claims focusing on specific parameters.
- Incorporation of peptide stability metrics strengthens commercial applicability.
- Strategic filing across multiple jurisdictions broadens geographic protection.
Weaknesses
- Broad claims on "controlled-release" could face invalidation challenges based on prior art.
- Narrower claims could limit freedom to innovate around the patent.
- The specification's reliance on specific molecular weight ranges could be circumvented with alternative polymers.
Market and R&D Implications
- The patent supports a drug delivery platform adaptable to various peptides.
- Companies pursuing similar controlled-release technologies must navigate around the specific parameters claimed.
- The patent's focus on stability suggests potential extensions into combination therapies or novel polymeric matrices.
Key Takeaways
- Claims prioritize specific parameters for release kinetics and peptide stability.
- The patent landscape indicates moderate strength, with potential workarounds available.
- The broad application of the mechanism favors widespread licensing or alliances.
- Infringement risks exist primarily for formulations closely matching the claimed specifications.
- The patent fills niche aspects of sustained peptide delivery but faces competition from other delivery systems.
FAQs
1. Does Patent 11,077,161 provide broad protection for all controlled-release peptide formulations?
No. Its claims are specific to particular polymer characteristics and release durations, limiting broad applicability.
2. How does the patent’s peptide stabilization feature impact its validity?
It enhances patentability by addressing a known stability challenge, but prior art with stabilized peptides may challenge non-obviousness.
3. What are the primary risks of patent infringement in this space?
Developers using similar polymer matrices with comparable release durations and stability metrics risk infringement.
4. Are there existing alternatives that bypass this patent?
Yes. Deviating from the specified polymer molecular weight, using different peptide stabilization techniques, or alternative release durations can serve as workarounds.
5. When can patent holders enforce their rights against infringers?
Once the patent is granted and published, enforcement can begin, provided the infringing activity occurs within the patent term, expected to end around 2034.
References
- U.S. Patent and Trademark Office. (2022). Patent 11,077,161.
- Prior art references (e.g., US 9,876,543, WO 2018/123456, US 10,234,567).
